Get started
Author

Saharat Aungsumart

Observed names: Aungsumart, S, S. Aungsumart
ORCID: 0000-0002-8183-348X
Observed ORCID: 0000-0002-8183-348X
OpenAlex ID: A5074208317
Clinical outcomes and predictive factors related to good outcomes in plasma exchange in severe attack of NMOSD and long extensive transverse myelitis: Case series and review of the literature
2017 · Saharat Aungsumart, Metha Apiwattanakul · Multiple Sclerosis and Related Disorders · 56
Benefits of eculizumab in AQP4+ neuromyelitis optica spectrum disorder: Subgroup analyses of the randomized controlled phase 3 PREVENT trial
2020 · Jacqueline Palace, Dean M. Wingerchuk, et al. · Multiple Sclerosis and Related Disorders · 41
PDF
Abnormal level of consciousness predicts outcomes of patients with anti-NMDA encephalitis
2018 · Saharat Aungsumart, Atina Ha, et al. · Journal of Clinical Neuroscience · 25
Efficacy and safety of monoclonal antibody therapy in patients with neuromyelitis optica spectrum disorder: A systematic review and network meta-analysis
2023 · Saharat Aungsumart, Sitaporn Youngkong, et al. · Frontiers in Neurology · 22
Tumefactive demyelinating lesions: a retrospective cohort study in Thailand
2024 · Tatchaporn Ongphichetmetha, Saharat Aungsumart, et al. · Scientific Reports · 21
PDF
Cost effectiveness of rituximab and mycophenolate mofetil for neuromyelitis optica spectrum disorder in Thailand: Economic evaluation and budget impact analysis
2020 · Saharat Aungsumart, Metha Apiwattanakul · PLoS ONE · 15
PDF
Cognitive Impairment and Risk Factors in Post-COVID-19 Hospitalized Patients
2023 · Jedsada Khieukhajee, Arada Rojana-udomsart, et al. · Dementia and Geriatric Cognitive Disorders Extra · 8
Importance of Calcium-Binding Site 2 in Simian Virus 40 Infection
2007 · Peggy P. Li, Albert P. Nguyen, et al. · Journal of Virology · 8
Efficacy and safety of oral amantadine in Parkinson’s disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials
2025 · Surachet Rujirussawarawong, Saharat Aungsumart, et al. · BMJ Neurology Open · 5
PDF
Rituximab for the treatment of relapsing-remitting multiple sclerosis in Thailand: an economic evaluation and budget impact analysis
2023 · Saharat Aungsumart, Saowalak Turongkaravee, et al. · BMC Health Services Research · 4
PDF
Prognostic factors for first relapse in Thai patients with neuromyelitis optica spectrum disorder
2017 · K. Suksuchano, S. Aungsumart, et al. · Journal of the Neurological Sciences · 4
Untitled
2007 · Saharat Aungsumart, Kulthida Vaeteewoottacharn, et al. · ScienceAsia · 4
PDF
Impact of COVID-19 and vaccination on multiple sclerosis (MS) and neuromyelitis optica spectrum disorder (NMOSD)
2025 · Metha Apiwattanakul, Chawarat Ounmuang, et al. · Multiple Sclerosis and Related Disorders · 2
Author Correction: Tumefactive demyelinating lesions: a retrospective cohort study in Thailand
2024 · Tatchaporn Ongphichetmetha, Saharat Aungsumart, et al. · Scientific Reports · 2
Clinical characteristic and prognosis of amyotrophic lateral sclerosis in a cohort of Thai patients
2023 · Narupat Suanprasert, Narumon Tiawijit, et al. · Neurology Asia · 2
PDF
Concurrent anterior and posterior visual pathway impairment in a patient treated with infliximab
2016 · Saharat Aungsumart, Metha Apiwattanakul · Journal of the Neurological Sciences · 2
Encephalitis associated with autoantibody binding to the anti-N-methyl-D-aspartate receptor: immunopathogenesis, mechanisms, and clinical characteristics
2015 · Metha Apiwattanakul, Adhasit Nawa-apisak, et al. · Neuroimmunology and Neuroinflammation · 2
Chemo-radio Resistance in Cervical Cancer Induced by HPV16 E7
2006 · Saharat Aungsumart, Kulthida Vaeteewoottacharn, et al. · 2
Efficacy of fresh frozen plasma and human albumin in therapeutic plasma exchange for refractory neuromyelitis optica spectrum disorders and multiple sclerosis exacerbation: A two-tertiary care center study
2026 · Bhume Kanokvichitra, Chutithep Teekaput, et al. · Multiple Sclerosis and Related Disorders · 1
Comparison of visual outcomes in patients with aquaporin 4 immunoglobulin g-positive, myelin oligodendrocyte glycoprotein immunoglobulin g-positive, and double seronegative optic neuritis following severe optic neuritis
2025 · Rawipreeya Laosirirat, Metha Apiwattanakul, et al. · Neuroimmunology Reports · 1
Clinical and fringe benefits of rituximab in multiple sclerosis treatment in a poor resource setting: Case series and cost analysis
2023 · Saharat Aungsumart, Metha Apiwattanakul · Multiple Sclerosis and Related Disorders · 1
Pmd20 Centrifugal Versus Membrane Therapeutic Plasma Exchange: Single Center Cost Benefit Analysis in Thailand
2019 · Y. Lee, M. Apiwattanakul, et al. · Value in Health · 1
Electrophysiology in Distinguishing Functional Tremor from Organic Tremor: A Systematic Review and Meta‐Analysis of Diagnostic Accuracy
2026 · Surachet Rujirussawarawong, Chawarat Ounmuang, et al. · Movement Disorders Clinical Practice
Clinical characteristics and prognosis of neuralgic amyotrophy of the brachial plexus: A retrospective study in the Thai population
2026 · Sahaphum Taemeeyapradit, Saharat Aungsumart, et al. · Neurology Asia
PDF
Baseline severe disability as a predictor of treatment escalation to rituximab in AQP4-IgG–positive NMOSD patients: A retrospective cohort study
2026 · Chayangkoon Siripornmongkol, Metha Apiwattanakul, et al. · Multiple Sclerosis and Related Disorders
Works count: 30
Citation count: 229
H-index: 8
I10-index: 6
Year
Topic
Type